The edition · Orthopaedics
Robotic knee replacement sharpens alignment, but the gains patients feel are modest
Plus what GLP-1 agonists do to muscle and bone, a negative colchicine trial in knee osteoarthritis, and why the 48-hour rule may not fit periprosthetic hip fractures.
The edition in brief
Today's orthopaedics edition leads on robotic total knee arthroplasty. A meta-analysis of 52 studies found robotic surgery improves component alignment and reduces outliers, with lower blood loss and shorter stay, but only modest short-term differences in what patients report and longer operative times — the long-term clinical payoff is still unproven. A large meta-analysis of GLP-1 receptor agonists found no effect on bone density or fractures and no change in osteoarthritis symptom scores, but a consistent loss of lean body mass, mostly tied to weight loss and of uncertain functional importance. A double-blind trial of colchicine for knee osteoarthritis was negative for pain, function and effusion, despite improving inflammatory biomarkers, so it does not support colchicine for symptom relief. A pearl reaffirms that a fragility fracture is osteoporosis until proven otherwise and should trigger bone-health treatment. The practice-changer is a target-trial-emulation study of periprosthetic hip fracture: once immortal-time bias was removed, early surgery showed no short-term mortality advantage, suggesting the 48-hour native-hip-fracture standard should not be assumed here solely to cut mortality — though avoidable delay is still not justified.
Robotic knee replacement improves alignment, with modest gains in how patients feel
Robotic knee replacement reliably improves alignment and trims blood loss and stay, but has not yet shown a meaningful advantage in patient-reported outcomes or implant survival.
GLP-1 agonists spare bone and joints but trim lean mass
GLP-1 agonists appear neutral for bone and joint symptoms but reduce lean mass — support at-risk patients with resistance exercise and protein.
Colchicine did not relieve knee osteoarthritis in a placebo-controlled trial
Colchicine did not relieve knee osteoarthritis pain, function or effusion at three months — it is not a symptom treatment for knee osteoarthritis.
A fragility fracture is osteoporosis until proven otherwise — act on it
After any fragility fracture, start bone-health assessment and treatment before discharge rather than leaving it to someone else.
The 48-hour rule may not apply to periprosthetic hip fractures
Do not assume the 48-hour native-hip-fracture target applies to periprosthetic hip fractures for mortality; allow time for stabilisation and planning, without avoidable delay.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this one is waiting in it.

Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for orthopaedics, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free